Atopic dermatitis (AD), commonly known as eczema, is not just an uncomfortable skin condition; it is also having significant economic repercussions on the lives of many Portuguese residents. A recent cross-sectional study has quantified this economic burden, emphasizing the disease’s far-reaching impacts on quality of life and workforce productivity.
The study focused on 204 diagnosed individuals between June 2019 and January 2020, utilizing surveys to assess the condition’s economic toll. The data revealed alarming findings—the average score for the Dermatology Life Quality Index (DLQI) was 9.4, indicating substantial effects on patients' day-to-day lives. The research uncovered a staggering 24% productivity loss due to AD, resulting in the equivalent of 50 workdays lost annually per affected individual.
Through labor market participation analysis, the researchers calculated the economic impact of AD at approximately €1.477 million. This figure is comprised of €43 million resulting from absenteeism (missed work) and €1.295 million associated with presenteeism (working with reduced productivity). Family members also play a role, contributing to missed workdays, leading to another €139 million being accounted for.
Additional analyses included the time spent managing the disease, valued at €311 million annually. This figure encompasses not only treatment and care but also indicates the vast amount of time patients dedicate to managing their symptoms—an average of 267 hours each year. The data also showed significant expenditures, with costs related to outpatient treatments shared between the National Health Service (NHS) at €218 million and patient out-of-pocket costs rising as high as €800 million.
AD's prevalence is concerning as it affects approximately 20% of children and 10% of adults globally, with many cases beginning during childhood. The overall burden of the disease has positioned AD as the leading skin condition impacting individuals' lives across various demographics.
The insights garnered from the study have led the authors to stress the importance of reassessing healthcare policies related to AD. They advocate for resource allocation toward more comprehensive healthcare services, improved access to dermatological care, and heightened awareness surrounding the disease's impacts. "Atopic dermatitis imposes significant economic burdens, and its impact often goes underestimated by policymakers and society, affecting quality of life and productivity for millions," noted the authors of the article.
This growing recognition of atopic dermatitis as not merely a medical condition but as a severe public health issue can help mobilize resources and intervention strategies to benefit affected individuals. Addressing both direct and indirect costs, and supporting patients through enhanced healthcare access and effective disease management strategies, will not only mitigate the immense financial burden but will also improve the quality of life for those suffering from this chronic disease.
The study serves as both a benchmark for future economic analyses of atopic dermatitis within Portugal, as well as for similar studies across Europe and beyond, highlighting pressing areas for healthcare policy reform and research development.